PF-06873600 is primarily investigated for its potential in cancer therapy, particularly as a CDK inhibitor. It targets cyclin-dependent kinases, which play a crucial role in cell cycle regulation. By inhibiting these kinases, it aims to halt the proliferation of cancer cells, making it a promising candidate for treating various types of cancers, including breast and ovarian cancer. Clinical trials are ongoing to evaluate its efficacy and safety in patients, with a focus on its ability to induce tumor regression and improve survival rates. Additionally, research explores its potential in combination therapies to enhance overall treatment outcomes.